Advertisement

Topics

Prof Terje Pedersen, SEAS Study Principal Investigator & Head of Steering Committee Company Profile

09:39 EDT 19th September 2017 | BioPortfolio


News Articles [2444 Associated News Articles listed on BioPortfolio]

SIR-Spheres® Y-90 Resin Microspheres Showed No Significant Difference in Overall Survival (OS) Compared to Sorafenib in Advanced HCC with Significantly Fewer Severe Adverse Events, New Asia-Pacific Study Finds

CHICAGO, June 5, 2017 /PRNewswire/ -- Final Results of SIRveNIB Study presented at 2017 American Society of Clinical Oncology Meeting For the second time in less than two months, a major ...

Bacterial Cell Shape Influenced by Mechanical Stress

Architecture isn’t limited to popular buildings from noted designers such Frank Gehry and the late Zaha Hadid, or great structures from ancient civilizations that remain standing. Form and function ...

Study findings suggest how progranulin deficiency causes frontotemporal dementia

In a recent study in Human Molecular Genetics, researchers from VIB and KU Leuven led by prof. Philip Van Damme, reveal a novel function for progranulin in lysosomes: it acts as chaperone of the lysos...

New Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With History Of Stroke

THOUSAND OAKS, Calif., Aug. 29, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a new analysis showed lowering low-density lipoprotein cholesterol (LDL-C) levels with Repatha®...

Scientists ID Tiny Prehistoric Sea Worm With 50 Spines

NewsLong before dinosaurs roamed the Earth, a bizarre creature with a Venus flytrap-like head swam the seas.Contributed Author: 

[Articles] Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

In this exploratory analysis of CheckMate 141, nivolumab stabilised symptoms and functioning from baseline to weeks 9 and 15, whereas investigator's choice led to clinically meaningful deterioration. ...

Shortage of progranulin is a frequent cause of frontotemporal dementia

In a recent study in Human Molecular Genetics, researchers from VIB and KU Leuven led by prof. Philip Van Damme, reveal a novel function for progranulin in lysosomes: it acts as chaperone of the lysos...

ESMO 2017 highlights on managing difficult to treat cancers

Prof Viktor Grünwald (Hannover Medical School, Hannover, Germany), Prof Richard Finn (Geffen School of Medicine at UCLA Medical Center, Los Angeles, USA), Prof Arndt Vogel (Hannover Medical School...

PubMed Articles [2010 Associated PubMed Articles listed on BioPortfolio]

Exploring Validation of a Graphic Symbol Questionnaire to Measure Participation Experiences of Youth in Activity Settings.

Participation has a subjective and private dimension, and so it is important to hear directly from youth about their experiences in various activity settings, the places where they "do things" and int...

Prof Stellos talks to Prof Steffens, awardee of the ESC/CBCS outstanding award, for 2016.

Reply to the Letter by Dr Peter Griffin and Prof. Andrew Curran, "Response to Article by Prof. Hans Kromhout, Hygiene Without Numbers".

Investigator Initiated Studies - Industry or Investigator - "Who Wins?"

Editorial for Special Issue: Approaches to Top-Down Proteomics: In Honour of Prof. Patrick H. O'Farrell.

Presaging the current discipline of Proteomics, Prof Patrick H. O'Farrell recognized the critical need for detailed protein analyses to dissect and thereby understand molecular mechanisms. [...].

Clinical Trials [2529 Associated Clinical Trials listed on BioPortfolio]

An Observational Follow-Up Study of the Incidence of Cancer and Mortality in Patients From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Trial

The purpose of this extension is to observe the incidence rates of cancer, total mortality, and mortality due to cancer over a 21 month follow-up period in patients from the SEAS trial (20...

Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

The purpose of this study is to find out whether Nivolumab will significantly improve progression-free survival and/or overall survival as compared to therapy of investigator's choice in p...

The Comparison of Core Stabilization Exercise With Scientific Exercise Approach to Scoliosis in Idiopathic Scoliosis

Scoliosis specific exercises have been shown to improve curve progression but there have been few studies that compare the different exercise approaches in adolescent idiopathic scoliosis ...

A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma

This is an open-label phase II, multicenter study. Eligible patients will receive CP-751,871 in monotherapy (20 mg/kg IV infusion on Day 1 of 3-week cycles). Tumor check-up will be perform...

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer

The purpose of this study is to provide access to paclitaxel therapy to subjects with advanced head and neck cancer who have completed the previous late phase 2 study (CA139-388) and shoul...

Companies [847 Associated Companies listed on BioPortfolio]

Prof Terje Pedersen, SEAS Study Principal Investigator & Head of Steering Committee

Visgenyx Ltd

Visgenyx Ltd was founded in 1999 by Prof. Alar Karis and Prof. Eero Vasar, both scientists at the University of Tartu, Estonia.An increasing demand for appropriate animal models for study of human dis...

The Principal Financial Group

The Principal Financial Group® (The Principal®)1 is a global investment management leader offering retirement services, insurance solutions and asset management. The Princip...

EpiSafe Medical Devices Ltd

EpiSafe is a privately held medical device company dedicated to the development and manufacture of medical devices for the oral cavity. It was founded in 2002 by Eran Lavi, who serves as CEO of the co...

Clinical Assistance Programs

Clinical Assistance Programs (CAP) is a clinical trial management organization. CAP provides site and data quality management, investigator training, and specialized compliance services to life scienc...

More Information about "Prof Terje Pedersen, SEAS Study Principal Investigator & Head of Steering Committee" on BioPortfolio

We have published hundreds of Prof Terje Pedersen, SEAS Study Principal Investigator & Head of Steering Committee news stories on BioPortfolio along with dozens of Prof Terje Pedersen, SEAS Study Principal Investigator & Head of Steering Committee Clinical Trials and PubMed Articles about Prof Terje Pedersen, SEAS Study Principal Investigator & Head of Steering Committee for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Prof Terje Pedersen, SEAS Study Principal Investigator & Head of Steering Committee Companies in our database. You can also find out about relevant Prof Terje Pedersen, SEAS Study Principal Investigator & Head of Steering Committee Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record